NEW YORK, Nov. 5, (GenomeWeb News) - Bruker BioSciences today reported revenues of $63 million for the third quarter ending Sept. 30, up over the $57 million for the year-ago quarter.
The company results reflect a merger-related charge of $6.4 million for the July 1 merger of Bruker Daltonics and Bruker AXS, and results from prior periods are historical combined reports of the two previously separate companies.
The company had a third-quarter net loss of $14.7 million, compared to a net income of $1.2 million for the year-ago quarter.
Bruker reported research and development costs of $9.6 million for the quarter, compared to $7.7 million for the same quarter last year. The firm reported cash, and short-term investments of $78 million for the quarter, as compared to $100 million for the year ago period.